Advanced search
Publication Cover
Ophthalmic Genetics Volume 43, 2022 - Issue 6: Special Issue: Festschrift: Dedicated to the life and work of A. Linn Murphree, MD
Submit an article Journal homepage
161
Views
0
CrossRef citations to date
0
Altmetric
Research Report

Iris melanoma outcomes based on the Cancer Genome Atlas (TCGA) classification in 78 consecutive patients

Elliot CherkasOcular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USAORCID Iconhttps://orcid.org/0000-0002-2137-0938View further author information
ORCID Icon,
Guy S. NegrettiOcular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USAView further author information
,
Jennifer S. ZeigerOcular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USAView further author information
&
Carol L. ShieldsOcular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USACorrespondence[email protected]
View further author information
Pages 736-741 | Received 04 Oct 2022, Accepted 24 Oct 2022, Published online: 03 Nov 2022

References

  • Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye. 2017;31(2):241–57. doi:10.1038/eye.2016.275.
  • Jensen OA. Malignant melanoma of the iris. A 25-year analysis of danish cases. Eur J Ophthalmol. 1993;3(4):181–88. doi:10.1177/112067219300300402.
  • Shields CL, Kaliki S, Furuta M, et al. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina. 2012;32(7):1363–72. doi:10.1097/IAE.0b013e31824d09a8.
  • Shields CL, Kaliki S, Shah SU, Luo W, Furuta M, Shields JA. Iris melanoma: features and prognosis in 317 children and adults. J Aapos. 2012;16(1):10–16. doi:10.1016/j.jaapos.2011.10.012.
  • Shields CL, Shields JA, Materin M, Gershenbaum E, Singh AD, Smith A. Iris melanoma: risk factors for metastasis in 169 consecutive patients. Ophthalmology. 2001;108(1):172–78. doi:10.1016/S0161-6420(00)00449-8.
  • Shah SU, Shields CL, Bianciotto C, Emrich J, Komarnicky L, Shields JA. Plaque radiotherapy for residual or recurrent iris melanoma after surgical resection in 32 cases. Ophthalmology. 2012;119(4):838–842.e832. doi:10.1016/j.ophtha.2011.09.039.
  • Shields CL, Furuta M, Thangappan A, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127(8):989–98. doi:10.1001/archophthalmol.2009.208.
  • Vichitvejpaisal P, Dalvin LA, Mazloumi M, Ewens KG, Ganguly A, Shields CL. Genetic analysis of uveal melanoma in 658 patients using the Cancer Genome Atlas classification of uveal melanoma as A, B, C, and D. Ophthalmology. 2019;126(10):1445–53. doi:10.1016/j.ophtha.2019.04.027.
  • Shields CL, Dalvin LA, Vichitvejpaisal P, Mazloumi M, Ganguly A, Shields J. Prognostication of uveal melanoma is simple and highly predictive using the Cancer Genome Atlas (TCGA) classification: a review. Indian J Ophthalmol. 2019;67(12):1959–63. doi:10.4103/ijo.IJO_1589_19.
  • Mazloumi M, Vichitvejpaisal P, Dalvin LA, Yaghy A, Ewens KG, Ganguly A, Shields CL. Accuracy of the Cancer Genome Atlas classification vs American joint committee on cancer classification for prediction of metastasis in patients with uveal melanoma. JAMA Ophthalmol. 2020;138(3):260–67. doi:10.1001/jamaophthalmol.2019.5710.
  • Shields CL, Mayro EL, Bas Z, Dockery P, Yaghy A, Lally S, Ganguly A, Shields J. Ten-year outcomes of uveal melanoma based on the Cancer Genome Atlas (TCGA) classification in 1001 cases. Indian J Ophthalmol. 2021;69(7):1839–45. doi:10.4103/ijo.IJO_313_21.
  • Sajjadi Z, Bas Z, Mayro EL, Ganguly A, Shields C. Outcomes of The Cancer Genome Atlas (TCGA) Classification in Uveal Melanoma by Patient Age in 1001 Eyes. Invest. Ophthalmol. Vis. Sci. 2021;62(8):40.
  • Shields C, Dockery P, Mayro E, Dockery P, Yaghy A, Lally S, Ganguly A, Shields J. Conditional survival of uveal melanoma using the Cancer Genome Atlas (TCGA) classification (simplified version) in 1001 cases. Saudi J Ophthalmol. 2022;0(7):0. doi:10.4103/ijo.IJO_313_21.
  • Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell. 2017;32(2):204–20.e215. doi:10.1016/j.ccell.2017.07.003.
  • Jager MJ, Brouwer NJ, Esmaeli B. The Cancer Genome Atlas project: an integrated molecular view of uveal melanoma. Ophthalmology. 2018;125(8):1139–42. doi:10.1016/j.ophtha.2018.03.011.
  • Gelmi MC, Bas Z, Malkani K, Ganguly A, Shields CL, Jager MJ. Adding the Cancer Genome Atlas chromosome classes to american joint committee on cancer system offers more precise prognostication in uveal melanoma. Ophthalmology. 2022;129(4):431–37. doi:10.1016/j.ophtha.2021.11.018.
  • Henderson E, Margo CE. Iris melanoma. Arch Pathol Lab Med. 2008;132(2):268–72. doi:10.5858/2008-132-268-IM.
  • SR KT, Grossniklaus HE. Uveal melanoma. AJCC Cancer Staging Manual. 2016;8:805–17.
  • Shields CL, Di Nicola M, Bekerman VP, Kaliki S, Alarcon C, Fulco E, Shields JA. Iris melanoma outcomes based on the American joint committee on cancer classification (eighth edition) in 432 patients. Ophthalmology. 2018;125(6):913–23. doi:10.1016/j.ophtha.2017.11.040.
  • Shields CL, Ramasubramanian A, Ganguly A, Mohan D, Shields JA. Cytogenetic testing of iris melanoma using fine needle aspiration biopsy in 17 patients. Retina. 2011;31(3):574–80. doi:10.1097/IAE.0b013e3181f57e62.
  • Krishna Y, Kalirai H, Thornton S, Damato BE, Heimann H, Coupland SE. Genetic findings in treatment-naïve and proton-beam-radiated iris melanomas: table 1. Br J Ophthalmol. 2016;100(7):1012–16. doi:10.1136/bjophthalmol-2015-308301.
  • Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1a):A68–77. doi:10.5114/wo.2014.47136.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.